Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination has received approval from the US Food and Drug Administration (FDA) to treat adults with Kirsten rat sarcoma virus gene (KRAS ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

At the same time, one of the latest milestones in Amgen's oncology franchise was the FDA approval of the combination of Lumakras and Vectibix on January 17 for the treatment of certain patients ...

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix in ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued to clients and investors on Wednesday, March 5th. William Blair analyst M.

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...

Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals ...